Whole blood <i>GRHL2</i> expression as a prognostic biomarker in metastatic hormone-sensitive and castration-resistant prostate cancer.

Transl Androl Urol · 2021 · PMC8100842 · PMID 33968657

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a strong trendno p-value reported

While there was a strong trend towards GRHL2 expression and shorter OS, it did not correlate with other clinical endpoints, perhaps reflecting the relatively small sample size of 37 patients.

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.